In addition to widespread immune-cold features, our exploratory analysis identified a small subset of liposarcomas with concurrent PD-L1 expression, CD8+ infiltration, and CD68/CD20 positivity, suggesting an immune-inflamed niche that may represent the fraction most likely to benefit from immunotherapy. Here, CD8A is linked to liposarcoma.